A new future for R&D?
Measuring the return from pharmaceutical innovation 2017
The eighth annual pharmaceutical innovation study by Deloitte UK's Centre for Health Solutions looks at the challenges the industry faces while highlighting the key strategies to help increase pipeline value.
Value-based care and medical technology
Assessing the value of medtech products and offerings
The health care ecosystem is in the midst of a shift from volume-based, fee-for-service (FFS) systems to value-based care (VBC) models. AdvaMed launched a Strategic Value Initiative with Deloitte Consulting LLP to develop principles and an approach for assessing the value of medical technologies.
How biopharma companies are bolstering R&D pipeline through deal-making
Sourcing research externally seems to be the preferred path for biopharma companies to strengthen their R&D pipeline. But when choosing from the three main options open to them—licensing, mergers and acquisitions, and joint ventures—what factors should they examine, and do deal types differ in the ways they accelerate development and deliver long-term value?